ATE309802T1 - Verwendung von cyclopamine zur behandlung von psoriasis und anderen hauterkrankungen - Google Patents

Verwendung von cyclopamine zur behandlung von psoriasis und anderen hauterkrankungen

Info

Publication number
ATE309802T1
ATE309802T1 AT03723620T AT03723620T ATE309802T1 AT E309802 T1 ATE309802 T1 AT E309802T1 AT 03723620 T AT03723620 T AT 03723620T AT 03723620 T AT03723620 T AT 03723620T AT E309802 T1 ATE309802 T1 AT E309802T1
Authority
AT
Austria
Prior art keywords
cyclopamine
corticosteroid
skin
lesions
treatment
Prior art date
Application number
AT03723620T
Other languages
English (en)
Inventor
Sinan Tas
Oktay Avci
Original Assignee
Sinan Tas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29247069&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE309802(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/TR2002/000017 external-priority patent/WO2002078704A1/en
Application filed by Sinan Tas filed Critical Sinan Tas
Application granted granted Critical
Publication of ATE309802T1 publication Critical patent/ATE309802T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03723620T 2002-04-19 2003-03-17 Verwendung von cyclopamine zur behandlung von psoriasis und anderen hauterkrankungen ATE309802T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/TR2002/000017 WO2002078704A1 (en) 2001-07-02 2002-04-19 Use of cyclopamine in the treatment of psoriasis
PCT/TR2003/000017 WO2003088964A1 (en) 2002-04-19 2003-03-17 Use of cyclopamine in the treatment of psoriasis and other skin disorders

Publications (1)

Publication Number Publication Date
ATE309802T1 true ATE309802T1 (de) 2005-12-15

Family

ID=29247069

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03723620T ATE309802T1 (de) 2002-04-19 2003-03-17 Verwendung von cyclopamine zur behandlung von psoriasis und anderen hauterkrankungen

Country Status (15)

Country Link
US (6) US7893078B2 (de)
EP (2) EP1411938B1 (de)
JP (1) JP2006512281A (de)
KR (4) KR20080096605A (de)
CN (2) CN101642458A (de)
AT (1) ATE309802T1 (de)
AU (1) AU2003230541B2 (de)
BR (1) BR0309396A (de)
CA (3) CA2452152A1 (de)
DE (1) DE60302348T2 (de)
DK (1) DK1496895T3 (de)
EA (1) EA200401355A1 (de)
ES (1) ES2253672T3 (de)
MX (1) MXPA04010294A (de)
WO (1) WO2003088964A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7291626B1 (en) 1998-04-09 2007-11-06 John Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
EP1235851B1 (de) 1999-10-13 2006-05-31 Johns Hopkins University School of Medicine Verbindungen zur regulierung des hedgehog-signalwegs, zusammensetzungen und verwendungen davon
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
CA2452151C (en) * 2001-07-02 2012-01-03 Sinan Tas Use of cyclopamine, an inducer of the differentiation and apoptosis of the basal cell carcinoma (bcc) cells, in the treatment of bcc's and other tumors that use the hedgehog/smoothened pathway for proliferation of apoptosis
US20170326118A1 (en) * 2001-07-02 2017-11-16 Sinan Tas Drug treatment of tumors wherein hedgehog/smoothened signaling is utilized for inhibition of apoptosis of tumor cells
EP1411938B1 (de) * 2001-07-02 2005-07-06 Tas, Sinan Verwendung von cyclopamine zur Herstellung eines Arzneimittels zur Behandlung von Psoriasis
AU2005280112B2 (en) * 2004-08-27 2012-07-19 Infinity Pharmaceuticals, Inc. Cyclopamine analogues and methods of use thereof
US20070281040A1 (en) * 2004-09-30 2007-12-06 The University Of Chicago Combination therapy of hedgehog inhibitors, radiation and chemotherapeutic agents
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
US9850311B2 (en) 2005-10-31 2017-12-26 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
EP1945202A2 (de) * 2005-11-11 2008-07-23 Licentia OY Säugetier-hedgehog-signalhemmer
WO2008121102A2 (en) * 2006-02-21 2008-10-09 The Regents Of The University Of Michigan Hedgehog signaling pathway antagonist cancer treatment
US20110034498A1 (en) * 2006-03-24 2011-02-10 Mcgovern Karen J Dosing regimens for the treatment of cancer
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
US8148147B2 (en) 2007-01-24 2012-04-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
RU2009137012A (ru) 2007-03-07 2011-04-20 Инфинити Дискавери, Инк. (Us) Аналоги циклопаминлактама и способы их применения
US7648994B2 (en) * 2007-03-07 2010-01-19 Infinity Discovery, Inc. Heterocyclic cyclopamine analogs and methods of use thereof
WO2009086451A1 (en) * 2007-12-27 2009-07-09 Infinity Pharmaceuticals, Inc. Methods for stereoselective reduction
US20100297118A1 (en) * 2007-12-27 2010-11-25 Macdougall John Therapeutic Cancer Treatments
MX2010006991A (es) * 2007-12-27 2010-09-30 Infinity Pharmaceuticals Inc Tratamientos de cancer terapeuticos.
WO2009099625A2 (en) * 2008-02-08 2009-08-13 The Board Of Regents Of The University Of Texas System Cyclopamine tartrate salt and uses thereof
GB0813740D0 (en) * 2008-07-28 2008-09-03 Angeletti P Ist Richerche Biologica Therapeutic compounds
DK2331136T3 (en) 2008-09-26 2018-03-05 Oncomed Pharm Inc FRIZZLED BINDING AGENTS AND APPLICATIONS THEREOF
WO2010080817A2 (en) * 2009-01-06 2010-07-15 Utah State University Carbohydrate-cyclopamine conjugates as anticancer agents
GB0900484D0 (en) 2009-01-13 2009-02-11 Angeletti P Ist Richerche Bio Therapeutic agent
CN102574791A (zh) 2009-08-05 2012-07-11 无限药品股份有限公司 环杷明类似物的酶促转氨基反应
GB0916608D0 (en) 2009-09-22 2009-11-04 Angeletti P Ist Richerche Bio Therapeutic compounds
US20110135739A1 (en) * 2009-11-06 2011-06-09 Bennett Carter Oral Formulations of a Hedgehog Pathway Inhibitor
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
US20110183948A1 (en) * 2010-01-15 2011-07-28 Infinity Pharmaceuticals, Inc. Treatment of fibrotic conditions using hedgehog inhibitors
CA2794674A1 (en) 2010-04-01 2011-10-06 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
US9376447B2 (en) 2010-09-14 2016-06-28 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
WO2014066328A1 (en) 2012-10-23 2014-05-01 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using wnt pathway-binding agents
US9359444B2 (en) 2013-02-04 2016-06-07 Oncomed Pharmaceuticals Inc. Methods and monitoring of treatment with a Wnt pathway inhibitor
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
BR112017026103B1 (pt) 2015-06-04 2023-10-03 Sol-Gel Technologies Ltd Composições tópicas com composto inibidor de hedgehog, sistema de entrega tópica e seus usos
CN110520097B (zh) 2017-01-06 2023-10-27 帕尔维拉治疗股份有限公司 Mtor抑制剂的无水组合物及其使用方法
EP3817743A4 (de) 2018-07-02 2022-07-06 Palvella Therapeutics, Inc. Wasserfreie zusammensetzungen von mtor-hemmern und verfahren zur verwendung
WO2020118095A1 (en) 2018-12-06 2020-06-11 OctoTech, Inc. Rf receiver architectures with parametric circuits
US20240293378A1 (en) * 2021-06-21 2024-09-05 Palvella Therapeutics, Inc. Methods and compositions for treating gorlin syndrome
EP4344410A1 (de) 2021-09-13 2024-04-03 Sinan Tas Effektive eingriffe bei alterung und alterungskrankheiten des menschen und deren folgen

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT73772B (en) * 1980-10-06 1983-10-14 Glaxo Group Ltd Topically administrable pharmaceutical compositions containing anti-inflammatory steroids
US5891465A (en) * 1996-05-14 1999-04-06 Biozone Laboratories, Inc. Delivery of biologically active material in a liposomal formulation for administration into the mouth
EP1019490B1 (de) 1997-02-10 2009-11-25 The President And Fellows Of Harvard College Verfahren zur modulation von hämatopoese und vaskulärem wachstum
US20050130922A1 (en) 1997-06-20 2005-06-16 Altaba Ariel R.I. Method and compositions for inhibiting tumorigenesis
US7741298B2 (en) 1997-06-20 2010-06-22 New York University Method and compositions for inhibiting tumorigenesis
US6238876B1 (en) 1997-06-20 2001-05-29 New York University Methods and materials for the diagnosis and treatment of sporadic basal cell carcinoma
US6867216B1 (en) * 1998-04-09 2005-03-15 Johns Hopkins University School Of Medicine Inhibitors of hedgehog signal pathways, compositions and uses related thereto
US7291626B1 (en) * 1998-04-09 2007-11-06 John Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
US6432970B2 (en) * 1998-04-09 2002-08-13 Johns Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
AU768130B2 (en) * 1998-04-09 2003-12-04 Johns Hopkins University School Of Medicine, The Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways
US6291516B1 (en) * 1999-01-13 2001-09-18 Curis, Inc. Regulators of the hedgehog pathway, compositions and uses related thereto
EP1183040B1 (de) * 1999-06-08 2004-12-01 Lorantis Limited Therapeutische verwendung eines inhibitors des hedgehog signalübertragungsweges
US20050080138A1 (en) 1999-09-16 2005-04-14 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
EP1235851B1 (de) * 1999-10-13 2006-05-31 Johns Hopkins University School of Medicine Verbindungen zur regulierung des hedgehog-signalwegs, zusammensetzungen und verwendungen davon
US6552016B1 (en) 1999-10-14 2003-04-22 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
EP1646395B8 (de) * 1999-11-30 2014-12-17 Curis, Inc. Verfahren und zusammensetzungen zur regulierung der lymphozytenaktivität
US6951839B1 (en) * 1999-11-30 2005-10-04 Curis, Inc. Methods and compositions for regulating lymphocyte activity
US6683108B1 (en) 2000-03-30 2004-01-27 Curis, Inc. Agonists of hedgehog signaling pathways and uses related thereto
US7115653B2 (en) 2000-03-30 2006-10-03 Curis, Inc. Small organic molecule regulators of cell proliferation
WO2001098344A2 (en) 2000-06-16 2001-12-27 Curis, Inc. Angiogenesis-modulating compositions and uses
US7498304B2 (en) 2000-06-16 2009-03-03 Curis, Inc. Angiogenesis-modulating compositions and uses
CU23175A1 (es) * 2000-07-17 2006-09-22 Ct De Investigacion Y Desarrol Formulacion liposomica de propionato de clobetasol
US20020165221A1 (en) 2000-10-13 2002-11-07 Baxter Anthony David Mediators of hedgehog signaling pathways, compositions and uses related thereto
US7708998B2 (en) 2000-10-13 2010-05-04 Curis, Inc. Methods of inhibiting unwanted cell proliferation using hedgehog antagonists
DK1387674T3 (en) 2000-10-13 2017-04-10 Curis Inc Hedgehog antagonists, methods and uses related thereto
AU2002247847A1 (en) 2001-04-09 2002-10-21 Lorantis Limited Therapeutic use and identification of modulators of a hedgehog signalling pathway or one of its target pathways
EP1411938B1 (de) 2001-07-02 2005-07-06 Tas, Sinan Verwendung von cyclopamine zur Herstellung eines Arzneimittels zur Behandlung von Psoriasis
CA2452151C (en) * 2001-07-02 2012-01-03 Sinan Tas Use of cyclopamine, an inducer of the differentiation and apoptosis of the basal cell carcinoma (bcc) cells, in the treatment of bcc's and other tumors that use the hedgehog/smoothened pathway for proliferation of apoptosis
PT1448205E (pt) * 2001-10-05 2011-07-05 Zalicus Inc Combinações para o tratamento de distúrbios munoinflamatórios
US6927205B2 (en) * 2003-04-28 2005-08-09 Procyte Corporation Compositions and methods for treatment of psoriasis
KR20050037103A (ko) 2003-10-17 2005-04-21 주식회사 엘지생활건강 피부 미백용 화장료 조성물
AU2005280112B2 (en) * 2004-08-27 2012-07-19 Infinity Pharmaceuticals, Inc. Cyclopamine analogues and methods of use thereof
WO2007024971A2 (en) * 2005-08-22 2007-03-01 The Johns Hopkins University Hedgehog pathway antagonists to treat disease

Also Published As

Publication number Publication date
US20040072913A1 (en) 2004-04-15
CA2481499A1 (en) 2003-10-30
EP1411938A1 (de) 2004-04-28
ES2253672T3 (es) 2006-06-01
DE60302348T2 (de) 2006-07-27
US7893078B2 (en) 2011-02-22
US20080089915A1 (en) 2008-04-17
BR0309396A (pt) 2005-02-09
WO2003088964A1 (en) 2003-10-30
EP1496895A1 (de) 2005-01-19
CA2481499C (en) 2013-05-21
CA2636960A1 (en) 2003-10-30
CA2452152A1 (en) 2002-10-10
US20110104254A1 (en) 2011-05-05
JP2006512281A (ja) 2006-04-13
KR20080094739A (ko) 2008-10-23
KR20080096605A (ko) 2008-10-30
KR20070108287A (ko) 2007-11-08
EA200401355A1 (ru) 2005-06-30
US9757361B2 (en) 2017-09-12
US20090286822A1 (en) 2009-11-19
CN101642458A (zh) 2010-02-10
DE60302348D1 (de) 2005-12-22
CN1835748A (zh) 2006-09-20
CA2636960C (en) 2013-12-31
US20040072914A1 (en) 2004-04-15
EP1411938B1 (de) 2005-07-06
MXPA04010294A (es) 2005-05-17
KR20040102117A (ko) 2004-12-03
EP1496895B1 (de) 2005-11-16
US20080090790A1 (en) 2008-04-17
US7629352B2 (en) 2009-12-08
US7605167B2 (en) 2009-10-20
US20100048725A2 (en) 2010-02-25
AU2003230541B2 (en) 2006-06-29
DK1496895T3 (da) 2006-03-27
AU2003230541A1 (en) 2003-11-03
US8025893B2 (en) 2011-09-27

Similar Documents

Publication Publication Date Title
ATE309802T1 (de) Verwendung von cyclopamine zur behandlung von psoriasis und anderen hauterkrankungen
CY1121447T1 (el) Συνθεσεις για αυξηση δραστηριοτητας τελομερασης
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
ATE380548T1 (de) Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie
CR8380A (es) Metodos para preparar y utilizar compuestos novedosos de celulas madre y sus conjuntos
SG146666A1 (en) Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
ATE347366T1 (de) Verwendung von activem vitamin d analoga zur behandlung von prostataerkrangkungen
IL172705A0 (en) Use of [3.2.0] heterocyclic compounds and analogs thereof for the treatment of cancer, inflammation and infectious diseases
WO2005030083A3 (en) Methods and products which utilize n-acyl-l-aspartic acid
ES2166783T3 (es) Factor viii activado utilizado como agente terapeutico y metodo para el tratamiento de la deficiencia de factor viii.
DE60042137D1 (de) Rekombinante alpha-l-iduronidase und behandlung von durch diese hervorgerufene mangelerkrankungen
BR0209922A (pt) Método para tratar uma condição médica que envolve a angiogênese em um paciente, para inibir a vascularização de células endoteliais, e para tratar câncer em um mamìfero
Joseph et al. Unilateral remission of psoriasis following traumatic nerve palsy
BR0111591A (pt) Compostos, composição farmacêutica, e, métodos para elevar o nìvel de plasma do hormÈnio de crescimento em um mamìfero, para o tratamento de deficiência da secreção do hormÈnio de crescimento, para o tratamento do retardo do crescimento em crianças, para o tratamento de distúrbios metabólicos associados com a deficiência da secreção do hormÈnio de crescimento, em particular em pacientes idosos, e para promover a cura de ferimentos, recupeção de cirurgia ou recuperação de doenças debilitantes
EA200600921A1 (ru) Способы и композиции с применением талидомида для лечения и менеджмента рака и других заболеваний
ATE453402T1 (de) Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
MY134562A (en) Methods and compositions to treat conditions associated with neovascularization
DE60330888D1 (de) Verwendung von drospirenon zur behandlung von hypertension
ATE311191T1 (de) Apoptotische körper zur verwendung in der behandlung von t-zell-vermittelten- und entzündungserkrankungen
ATE230609T1 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
DE69825279D1 (de) Verwendung von glukosamin und glukosaminderivaten zur schnellen linderung von juckreiz oder lokalisiertem schmerz
MXPA05008561A (es) Uso de esteroides para tratar personas que sufren de trastornos oculares.
TW200501934A (en) Therapeutic causing contraction of mucosal tissue, method of treating diseases relating to mucosal tissues, injector and therapeutic set
MXPA00010254A (es) Tratamiento de disfuncion sexual en ciertos grupos de pacientes.
ATE556134T1 (de) Mesenchymstammzellen und verwendungendafür

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1496895

Country of ref document: EP

REN Ceased due to non-payment of the annual fee